Literature DB >> 9249113

Postischemic brain injury is affected stereospecifically by pentazocine in rats.

H Takahashi1, R J Traystman, K Hashimoto, E D London, J R Kirsch.   

Abstract

We tested whether rats treated with the sigma1-receptor ligand, (+)-pentazocine, during transient focal ischemia would have a smaller volume of postischemic brain infarction than rats treated with the nonspecific opioid-receptor ligand (-)-pentazocine. Rats underwent focal cerebral ischemia using the filament occlusion technique for 2 h, followed by 22 h of reperfusion. Rats received (+) or (-)-pentazocine (n = 9 each group) at a dose of 2 mg x kg(-1) x h(-1) by continuous intravenous infusion from 1 h of ischemia to 22 h of reperfusion. Triphenyltetrazolium-determined infarction volume of ipsilateral striatum ([+]-pentazocine, 19 +/- 4 mm3, mean +/- SEM; [-]-pentazocine, 44 +/- 5 mm3) and cerebral cortex ([+]-pentazocine, 26 +/- 12 mm3; [-]-pentazocine, 134 +/- 29 mm3) was smaller in rats treated with (+) compared with (-)-pentazocine. Infarction volume in rats treated with (-)-pentazocine was also very similar to the infarction volume in saline-treated control rats from our previous study (striatum 44 +/- 4 mm3; hemisphere 136 +/- 27 mm3). These data indicate that sigma1-receptors may play an important role in the mechanism of injury both in cortex and striatum after 2 h of transient focal ischemia in rat.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9249113     DOI: 10.1097/00000539-199708000-00020

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  7 in total

1.  Administration of a Sigma Receptor Agonist Delays MCAO-Induced Neurodegeneration and White Matter Injury.

Authors:  Christopher C Leonardo; Aaron A Hall; Lisa A Collier; Suzanne M Green; Alison E Willing; Keith R Pennypacker
Journal:  Transl Stroke Res       Date:  2010-06       Impact factor: 6.829

2.  Analysis of sigma receptor (sigmaR1) expression in retinal ganglion cells cultured under hyperglycemic conditions and in diabetic mice.

Authors:  M Shamsul Ola; Pamela Moore; Dennis Maddox; Amira El-Sherbeny; Wei Huang; Penny Roon; Neeraj Agarwal; Vadivel Ganapathy; Sylvia B Smith
Journal:  Brain Res Mol Brain Res       Date:  2002-11-15

3.  Implications of immune system in stroke for novel therapeutic approaches.

Authors:  Aaron A Hall; Keith R Pennypacker
Journal:  Transl Stroke Res       Date:  2010-01-13       Impact factor: 6.829

4.  Sigma receptor agonists provide neuroprotection in vitro by preserving bcl-2.

Authors:  Sufang Yang; Anish Bhardwaj; Jian Cheng; Nabil J Alkayed; Patricia D Hurn; Jeffrey R Kirsch
Journal:  Anesth Analg       Date:  2007-05       Impact factor: 5.108

5.  Cyclic adenosine monophosphate response element-binding protein phosphorylation and neuroprotection by 4-phenyl-1-(4-phenylbutyl) piperidine (PPBP).

Authors:  Sufang Yang; Nabil J Alkayed; Patricia D Hurn; Jeffrey R Kirsch
Journal:  Anesth Analg       Date:  2009-03       Impact factor: 5.108

6.  Poly (ADP-ribose) polymerase-1 initiated neuronal cell death pathway--do androgens matter?

Authors:  K Vagnerova; K Liu; A Ardeshiri; J Cheng; S J Murphy; P D Hurn; P S Herson
Journal:  Neuroscience       Date:  2009-12-24       Impact factor: 3.590

7.  The Sigma-1 Receptor Antagonist, S1RA, Reduces Stroke Damage, Ameliorates Post-Stroke Neurological Deficits and Suppresses the Overexpression of MMP-9.

Authors:  Pilar Sánchez-Blázquez; Andrea Pozo-Rodrigálvarez; Manuel Merlos; Javier Garzón
Journal:  Mol Neurobiol       Date:  2017-08-05       Impact factor: 5.590

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.